Cyteir Therapeutics, Inc. (CYT): Price and Financial Metrics


Cyteir Therapeutics, Inc. (CYT): $1.71

0.12 (+7.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYT Stock Price Chart Interactive Chart >

Price chart for CYT

CYT Price/Volume Stats

Current price $1.71 52-week high $7.31
Prev. close $1.59 52-week low $1.13
Day low $1.56 Volume 49,400
Day high $1.71 Avg. volume 209,761
50-day MA $1.49 Dividend yield N/A
200-day MA $2.14 Market Cap 60.42M

Cyteir Therapeutics, Inc. (CYT) Company Bio


Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.


CYT Latest News Stream


Event/Time News Detail
Loading, please wait...

CYT Latest Social Stream


Loading social stream, please wait...

View Full CYT Social Stream

Latest CYT News From Around the Web

Below are the latest news stories about CYTEIR THERAPEUTICS INC that investors may wish to consider to help them evaluate CYT as an investment opportunity.

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

LEXINGTON, Mass., November 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights.

Yahoo | November 7, 2022

Great news for Cyteir Therapeutics, Inc. (NASDAQ:CYT): Insiders acquired stock in large numbers last year

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | October 22, 2022

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

LEXINGTON, Mass., October 12, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targ

Yahoo | October 12, 2022

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

LEXINGTON, Mass., August 31, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022.

Yahoo | August 31, 2022

We're Keeping An Eye On Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | August 24, 2022

Read More 'CYT' Stories Here

CYT Price Returns

1-mo 16.33%
3-mo -7.07%
6-mo -41.24%
1-year -69.63%
3-year N/A
5-year N/A
YTD 3.64%
2022 -85.49%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.777 seconds.